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Abstract 
Objective 
To determine the effect of a low lying placenta on the concentration of quantita-
tive fetal fibronectin (qfFN) in the cervicovaginal fluid (CVF), and predictive accu-
racy for spontaneous preterm birth in asymptomatic high-risk women (18+0-24+0 
weeks gestation). 
Methods 
Median concentrations of qfFN were compared in women who had a low lying pla-
centa, covering the cervical os (n = 61) to matched controls (n= 61) without a low 
lying placenta. Proportions of women with raised qfFN concentrations (>10ng/ml), 
and false positive and negative rates (FPR and FNR) for spontaneous preterm de-
livery were also compared.  
Results 
The median concentration of qfFN in women with low lying placenta was 5.0 
ng/mL, compared with 6.0 ng/mL in controls. Proportion of women with raised 
levels (>10 ng/mL), positive levels (>50ng/mL) and very high levels (>200ng/mL) 
were similar in both groups (62.3% vs 59.0%, 16.3% vs 22.0% and 6.5% vs 4.9%, 
p>0.05 for all thresholds). The FPR and FNR rate for delivery before 34 and 37 
weeks were also comparable (FPR 90.0% vs 85.7% and 80.0% vs 78.6%; FNR 5.8% vs 
4.3% and 9.8% vs 8.5%) 
Conclusions 
CVF qfFN concentrations in asymptomatic high-risk women are not affected by the 
presence of a low-lying placenta.   
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Introduction 
 
Preterm birth (PTB) is a major cause of neonatal morbidity and mortality world-
wide; accurate identification of those women who are at greatest risk facilitates 
treatment, including targeted administration of steroids or in utero transfer, po-
tentially improving fetal outcome, and reducing unnecessary treatment of those 
destined to deliver closer to term.   
  
Fetal fibronectin (fFN) is a leading predictor of spontaneous PTB (sPTB)1,2.  fFN is 
an extracellular matrix protein, found at the interface of the fetal membranes and 
decidua. Although it is commonly found in the cervicovaginal fluid (CVF) before 18 
weeks and later as labour approaches, it usually  present in low concentrations be-
tween 18 and 37 weeks of gestation 3. Higher concentrations of fFN detected in the 
CVF after 18 weeks may indicate disruption between this interface and is associat-
ed with subsequent sPTB. Initial studies demonstrated that detection (>50 ng/mL) 
confers a six-fold risk for sPTB before 35 weeks and 14-fold risk for birth before 28 
weeks 4.  
 
fFN testing is recommended in clinical practice for the identification of true pre-
term labour in those with symptoms and as a screening tool for high-risk asympto-
matic women 1,5-7  Used as a qualitative test (Rapid fFN Casette: TLiIQ
®
 system), a 
positive or negative result is generated at a threshold of 50 ng/mL. It has been 
demonstrated that quantification of actual fFN concentration (qfFN) improves pre-
diction of sPTB, providing alternative thresholds at which to define high and low 
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risk in both symptomatic and asymptomatic high risk women8,9. Quantification can 
now be performed with a bed-side test (Rapid fFN Cassette: 10Q System®).   
 
In certain circumstances, including vaginal bleeding, recent sexual intercourse and 
low lying placenta, the concentration of fibronectin and predictive value of the 
test may be affected due to interference with the enzyme linked immunosorbent 
assay (ELISA). Additionally there is the theoretical potential that a low lying pla-
centa my cause increased fFN secretion into cervico-vaginal fluid10-12. However, 
the predictive value of fetal fibronectin in women with a low lying placenta or pla-
centa praevia has never been formally assessed.   
 
The aim of this study was to examine the median concentrations of fetal fibron-
ectin, the proportion of women with a raised concentration of fibronectin (>10 
ng/ml) and the incidence of false positive and false negative rates (with a positive 
result defined as >50ng/mL for prediction of spontaneous delivery prior to 34 and 
37 weeks of gestation) in asymptomatic women between 18+0 and 24
+0 who were 
deemed to be at high-risk of preterm birth and who had a low placenta (defined as 
covering the internal cervical os) compared with a matched group of high-risk 
women who do not have a low placenta.     
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Materials  
 
This study is a prospective masked sub-analysis of a larger observational study 
(Evaluation of Quantitative fetal fibronectin in the Prediction of Preterm Birth – 
EQUIPP) which included data from 6 UK hospital sites collected between October 
2010 through July 2014 of CVF qfFN concentration and obstetric outcomes in wom-
en deemed to be at high risk of preterm birth.  Ethical approval was obtained from 
the South East London Research Ethics Committee. Written informed consent was 
obtained from all participants prior to involvement.  Women were eligible to take 
part in the study if they were between 18 +0 and 24+0 weeks of gestation, and con-
sidered high risk for pre-term birth; one or more of previous preterm birth (<37 
weeks), previous premature rupture of membranes (PROM) <37 weeks, previous 
late miscarriage (16-23+6 weeks), previous invasive cervical surgery (e.g. large loop 
excision of the transformation zone, cone biopsy), uterine abnormality, or a cervi-
cal length less than 25 mm in the current pregnancy. Gestational ages were con-
firmed with standard early ultrasound scans.  Participant baseline demographics, 
obstetric history and risk factors were entered onto an online secure study specific 
database (www.medscinet.net/ptbstudies) 
 
Eligible women underwent CVF fetal fibronectin testing between 18 +0 and  24
+0 
weeks of gestation.  qfFN swabs were taken according to  the manufacturer’s in-
structions; during speculum examination, dacron swabs were placed in the posteri-
or fornix and rotated for 10 seconds to become fully saturated. The swabs were 
placed in a buffer containing a specific monoclonal antibody (FDC-6) against the 
oncofetal domain of fFN 13,14. Aliquots were then analysed simultaneously with the 
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commercially available qualitative analyser, Rapid fFN Cassette: TLiIQ
®
,
 and quanti-
tative analyser, Rapid fFN Cassette: 10Q System®. The qualitative fFN result was 
made available to the clinician (positive at a value >50 ng/mL), whereas the quan-
titative concentration remained masked (random code generation).  Samples from 
women who reported prior sexual intercourse (within 24 hours), who had con-
firmed or suspected rupture of membranes, or who had frank bleeding visible on 
the swab were excluded from analysis due to known interference with fetal fi-
bronectin measurement. If a transvaginal ultrasonographic cervical length was per-
formed, this was done after the swab was taken. 
 
For this sub-analysis, asymptomatic high-risk women between 18+0 and 24+0 weeks 
of gestation, who during ultrasound scanning, were found to have a placenta cov-
ering the internal os were included in the study as having a low lying placenta and 
considered ‘cases’.  Cases were matched with asymptomatic high-risk women from 
the same database without low-lying placenta according to the following: risk fac-
tor for preterm birth (previous sPTB, previous PROM, previous late miscarriage [16-
23+6 weeks], invasive cervical surgery, uterine anomaly, or cervical length <25 mm 
in current pregnancy) and both gestational age at testing and delivery (+/- 7 days).   
 
Statistical analysis was performed using State software (version 12.0; Stata-Corp 
LP, College Station, TX). Women undergoing iatrogenic delivery before 37 weeks 
and 34 weeks of gestation were excluded from the analysis. 
 
Standard distributional checks were carried out. Quantitative fFN values were 
found to be highly asymmetric, with large standard deviations compared with the 
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means in both groups of women. Values were therefore logged using lnskew 
(0.0468) using censoring to accommodate for qfFN concentrations ‘0’ and >500 
ng/ml, and checks repeated. Geometric means were generated after transfor-
mation of log-normal distributions.  The qfFN values were compared between 
groups using Student t tests on the logged values. Results are reported as ratios of 
geometric means. Linear regression was used to look for differences in the qfFN 
levels according to placental location. To allow for matching, robust standard er-
rors were used.  
 
The number and percentages of women who tested within each concentration cat-
egory of qfFN (<10, 10-49 >50-199, >200 and >500 ng/mL) was analysed for cases 
and controls. These were compared using a chi-squared test.  
 
Delivery before 37 weeks gestation with a qfFN concentration greater than 
50ng/mL was defined as a true-positive result; likewise a false positive result was 
defined as cervicovaginal qfFN concentrations ≥ 50ng/mL at testing and delivery 
after 37 weeks of gestation. The false-positive and false negative rates in women 
with a term delivery were compared between the cases and controls. Analysis was 
repeated for prediction of delivery before 34 weeks of gestation. 
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Results 
 
A total of 62 participants with singleton pregnancies between and 18+0 and 24+0 
weeks’ gestation who had a low-lying placenta at the time of testing were identi-
fied. One woman was excluded from the analysis because of iatrogenic preterm 
delivery, leaving a total of 61 women fulfilling criteria for analysis. Demographic, 
obstetric and background characteristics for study participants are described in 
Table 1. 
 
[Insert Table 1 here ] 
 
The mean gestational age for both groups at testing was 21+3 (range 18+0 to 24+6) 
and the mean gestational age at delivery was 38+3 (range 19+3 to 41+6). The sPTB 
rate was 6.6% (4/61) (95% Confidence Interval [CI]: 1.8-15.9) at less than 34 weeks’ 
gestation and 11.5% (7/61) (CI: 4.7-22.2) at less than 37 weeks’ gestation.  
 
The median concentration of qfFN in the women who had low lying placenta was 
5.0 ng/mL (quartiles 3.0, 18.0), compared with 6.0 ng/mL (quartiles 3.0, 36.0) in 
the control group. The mean concentration of qfFN in women who had a low-lying 
placenta was 41.9 ng/mL compared with 47.0 ng/mL in the control group. The 
mean concentration of qfFN in the two groups did not differ significantly (mean 
difference 0.82 [CI: 0.43-1.53], ratio of geometric means cases vs controls; 7.67 
and 9.31 ng/mL p= 0.548). The distribution of qfFN concentrations for low lying 
placenta and controls are summarized in Figure 1. 
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[Insert Figure 1 here: Figure 1: Dot Plot of Fetal Fibronectin Results in Low Ly-
ing Placenta and Controls Illustrating a Similar Distribution of qfFN Results in 
Both Groups ] 
 
The number and proportion of women with qfFN concentration (ng/mL) in each 
category (<10, 10-49, 50-199, 200-499, >500 ng/ml) is summarized in table 2.  
38/61 (62.3%) of the cases and 36/61 (59.0%) of the controls had fFN concentra-
tions <10ng/mL (chi square 0.65, p>0.05). 10/61 (16.3%) and 14/61 (22.9%) of the 
cases had positive results by our predefined criteria, (concentrations >50ng/mL, 
chi square 1.37, p>0.05).   
 
[Insert Table 2 here ] 
 
For prediction of delivery before 34 weeks of gestation, there was no statistical 
difference in the false positive rate or false negative rate in women with a low 
placenta compared with controls; false positive rate in the low lying placenta 
group was 9/10 (90.0%)  vs. 12/14 (85.7%) in the control group (difference 5.3%; p 
= 0.47). The false-negative rate was 3/51 (5.8%) vs 2/47 (4.3%) in the controls (dif-
ference 1.6%; p= 0.47). The false positive rate for delivery before 37 weeks in the 
low lying placenta group was 8/10 (80.0%) vs 11/14 (78.6%) in the control group 
(difference 2.4%; P = 0.45). The false negative rate was 5/51 (9.8%) in the low ly-
ing placenta group and 4/47 (8.5%) in the control group (difference 6.3%; P = 
0.58). 
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Discussion 
 
This is the first study to report the effect of low-lying placenta on CVF qfFN con-
centrations in the pregnant population.  The results demonstrate that there is no 
difference in CVF qfFN concentration between women with a low lying placenta, 
and those whose placenta does not partially or wholly obscure the cervical os.  
Contrary to common belief, the presence of a low-lying placenta does not preclude 
the use of qfFN as a predictive test for preterm birth in this population.   
 
Consistent with other studies, the qfFN concentrations in both the low placenta 
and control groups were low8,9 . Approximately 60% of swab results were 
<10ng/mL, compared to 5-6% of women with results >200 ng/ml.  Only one of the 
cases and two of the controls had results >500ng/mL. There was no statistical or 
clinically relevant difference in proportions of case and controls falling into each 
of the qfFN concentration categories. 
 
Our study population demographics and sPTB rates are comparable to previously 
published preterm prediction studies7. Moreover there was a varied ethnic origin 
and thus the test can be considered transferable to a broad population.  5 women, 
4 cases and 1 control, underwent cerclage (history or ultrasound indicated) for 
prevention of preterm birth (progesterone was not routinely prescribed in the UK 
at the time of study data collection).  Given the relative rarity of a low placenta at 
this gestation, the small sample size precluded analysis of the predictive power of 
qfFN for meaningful clinical outcomes.  However the fact that the median levels of 
fetal fibronectin, the proportion with raised levels of fibronectin and the incidence 
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of false positive and negative rates in women with a low placenta is comparable to 
those without low lying placenta is reassuring. This indicates that low lying placen-
ta does not interfere with the ELISA nor cause increased fFN secretion into cervico-
vaginal fluid. 
 
The prevalence of placenta praevia at term (placenta which has implanted in the 
lower uterine segment) is 5.2 per 1000 and is thought to be on the rise secondary 
to the increased incidence of caesarean sections in the past three decades13. Nu-
merous risk factors have been associated including previous uterine surgery and 
advanced maternal age, multiparity, smoking, cocaine abuse, history of induced 
abortions and multiple pregnancies – risk factors which also confer risk for 
sPTB14,15. It is associated with poor maternal and neonatal outcomes16. 
 
At earlier gestations, a placenta partially or totally covering the os is more com-
mon, and this becomes less common with increasing gestational age, thought to be 
thought to be due to placental migration19.  Whilst the incidence of placenta prae-
via at weeks 18-24 of gestation ranges from 0.97-5.3%, there is a 90% resolution 
rate by the third trimester20-22.  
 
As many of the women screened with fetal fibronectin (either due to a previous 
history of preterm birth, or other obstetric risk factor) are well into their second 
trimester, it is likely that a significant proportion will have pregnancies complicat-
ed by low lying placentas. These are all women who may benefit from qfFN test-
ing.  Our findings that a  low lying placenta has no effect on the levels of qfFN nor 
incidence of false positive or negative results, is reassuring.  Moreover, the qfFN 
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test was used successfully in 62 women with low lying placenta without any ad-
verse events, including bleeding. Therefore it is reasonable to offer this test to 
women between 18 and 24 weeks of gestation regardless of their placental loca-
tion, as long as the other caveats to qfFN testing are fulfilled.  
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Tables 
Table 1: Demographic and Obstetric Characteristics 
Characteristic 
Low Lying Placen-
ta 
n = 61 
Number (%) 
Control  
n = 61 
Number (%) 
Maternal age 34 ± 4 32 ± 5 
Gestation age at testing 21
3/7 ± 22/7 213/7 ±21/7 
Gestational age at delivery 38
3/7 ± 32/7 384/7 ± 42/7 
Ethnicity 
White 37 (61) 28 (46) 
Black 17 (28) 24 (39) 
Asian 3 (5) 
0 (0) 
Other 4 (7) 9 (15) 
Obstetric Risk Factor 
Previous spontaneous preterm birth 16 (26) 16 (26) 
Previous PPROM 11 (18) 11 (18) 
Previous late miscarriage 12 (20) 12 (20) 
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Previous cervical surgery 27 (45) 27 (45) 
Multiple pregnancy 2 (3) 2 (3) 
Cervical length <25 mm 6 (10) 6 (10) 
Smoking  
Current 4 (7)  5 (8) 
Ex-smoker 5 (8) 15 (25) 
Never 52 (85) 41 (67) 
Other Risk Factors 
Past or present history of domestic vio-
lence 3 (5) 
1 (2) 
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Table 2: Proportion of Women in Each Quantification of fFN 
fFN Results (ng/mL) 
Low Lying Placenta 
n = 61 
Number (%) 
Control 
n = 61 
Number (%) 
<10  38 (62) 36 (59) 
10 - 49 13 (21) 11 (18) 
50 - 199 6 (10) 11 (18) 
200 - 499 3 (5) 
1 (2) 
>500 1 (2) 2 (3) 
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